Skip to main content
. Author manuscript; available in PMC: 2020 Dec 8.
Published in final edited form as: Clin Cancer Res. 2020 Feb 4;26(9):2216–2230. doi: 10.1158/1078-0432.CCR-18-3626

Figure 4.

Figure 4.

Improved response to TriVax vaccination. Mice were vaccinated by emulsion vaccine subcutaneously or TriVax vaccine retro-orbitally. Blood was collected and lysed by ACK, then cells from blood were stained with DimerX Db-GARC-1 (recognizing GARC-1–specific CD8+ T cells) and anti-CD8 antibody followed by flow cytometry analysis. Mean and SEM, n = 3. A, The percentage of GARC-1–specific CD8+ T cells generated by emulsion vaccine among all CD8+ T cells in the blood. B, The percentage of GARC-1–specific CD8+ T cells generated by TriVax vaccine among all CD8+ T cells in the blood. C, Survival of tumor-bearing mice treated with TriVax vaccination, intratumoral vvDD-IL15Rα-YFP, rapamycin, and celecoxib. Mice received tumor on day 0; TriVax vaccination on day 4; and 1 μL virus (2 × 106 pfu) or PBS injection, rapamycin, and celecoxib on day 7 (medication treatment continued until day 73). Mice that received the combination treatment lived significantly longer than the control group, P < 0.001.